Therapy Areas: Inflammatory Diseases
Cumberland Pharmaceuticals reports ifetroban Phase 2 DMD heart disease trial results
24 June 2025 - Cumberland Pharmaceuticals Inc (NASDAQ: CPIX), a US-based specialty pharmaceutical company, on Monday announced the latest positive results from its Phase 2 FIGHT DMD trial evaluating i...
European Commission approves argenx's VYVGART subcutaneous injection with Halozyme's ENHANZE for CIDP
23 June 2025 - Halozyme Therapeutics Inc (NASDAQ:HALO) announced on Friday that Dutch immunology company argenx SE (Euronext Brussels:ARGX) (Nasdaq:ARGX) has received European Commission approval for ...
FDA approves Dupixent as first targeted therapy for rare skin disease bullous pemphigoid
20 June 2025 - French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) announced on Friday that the US Food and Drug Administration has approved Dupixent (dupilumab) as the first targe...
Hoth Therapeutics regains Nasdaq compliance
19 June 2025 - US-based clinical-stage biopharmaceutical company Hoth Therapeutics Inc (NASDAQ: HOTH) announced on Wednesday that it has regained full compliance with Nasdaq's minimum bid price r...
TME Pharma and SERI partner to advance NOX-E36 in ophthalmology through option framework agreement
18 June 2025 - TME Pharma N.V. (Euronext Growth Paris: ALTME) announced on Wednesday that it has signed an option framework agreement with the Singapore Eye Research Institute (SERI) to advance the de...
Merry Life launches TML-6 global Phase II trial for Alzheimer's Disease
13 June 2025 - Taiwan-based Merry Life Biomedical Company announced on Thursday the launch of its global Phase II clinical trial for TML-6, a novel oral small molecule drug targeting early-stage Alzhe...